T1	Participants 109 156	prevention of relapse in gastric ulcer patients
T2	Participants 424 455	401 H. pylori-positive patients
T3	Participants 888 925	Patients with unhealed GUs at 4 weeks
T4	Participants 966 981	Healed patients
T5	Participants 1172 1291	Significantly more patients receiving EAC than those receiving esomeprazole alone remained free of GUs during follow-up
